We evaluated the impact of olanzapine on metabolic changes in patients with psychotic disorders. This was a retrospective cohort study involving patients prescribed olanzapine and attending Sultan Qaboos University Hospital (Muscat, Oman). Patients were followed up retrospectively from March 2006 until April 2021. Cardiovascular treatment targets were evaluated as per the 2019 European Society of Cardiology guidelines. We enrolled 253 patients (mean age: 40±17 years). Olanzapine monotherapy was associated with increased body weight (+8 kg; 95% confidence interval (CI): 6–9; P
CITATION STYLE
Al-Tobi, Z., Al Suleimani, Y., Al-Rasadi, K., Al-Shabibi, S., Al Mahrizi, A., Al-Maqbali, J., … Al-Zakwani, I. (2022). Metabolic Side Effects of Olanzapine in Patients With Psychotic Disorders in Oman: A Retrospective Cohort Study. Angiology, 73(10), 976–984. https://doi.org/10.1177/00033197211072340
Mendeley helps you to discover research relevant for your work.